Penicillin-resistant <i>Streptococcus dysgalactiae</i> subsp. <i>equisimilis</i> and the association with penicillin-binding protein mutations: a population genotypic and phenotypic study
ABSTRACT Streptococcus dysgalactiae subspecies equisimilis (SDSE) is increasingly recognized as a cause of human disease. Despite decades of penicillin use, SDSE is near universally penicillin-susceptible. Here we report and characterize by whole genome sequencing (WGS) three penicillin-resistant SDSE isolates (minimum inhibitory concentration [MIC] ≥0.256 mg/L) isolated from blood and skin in an individual with recurrent cellulitis on penicillin prophylaxis. The isolates carried 11 penicillin-binding protein (PBP) PBP2x, five PBP1a, and one PBP2b mutations that were distinct from the only previously reported WGS-characterized penicillin-resistant SDSE isolates ( n = 4). We then took a genotype-led approach to test the MICs of penicillin and amoxicillin for 63 isolates with PBP2x, PBP1a, and PBP2b variants selected from a well-characterized database of invasive SDSE isolates from Australia (2011–2023, n = 436). PBPs were highly conserved in Australian invasive SDSE genomes. Only a single isolate carrying a PBP2x variant with five mutations around the penicillin-binding cleft found in 1/436 invasive isolates demonstrated a four-fold rise in penicillin MIC, although remaining below clinical breakpoints. Strains with PBP2b and PBP1a variants alone were not associated with raised MICs. To provide broader context for PBP variants, we then examined a global database of SDSE genomes ( n = 1,160). PBP2x mutations in isolates with raised and/or resistant penicillin MICs were found in only nine global SDSE database genomes. SDSE penicillin resistance is rare and associated with multiple PBP mutations, particularly PBP2x. WGS with phenotypic testing of novel PBP variants could be used to monitor emerging mutations associated with raised penicillin MICs.
Authors
- Tony M. Korman (ORCID: https://orcid.org/0000-0002-6155-8353)
- Katherine A. Bond (ORCID: https://orcid.org/0000-0002-4473-9232)
- Ouli Xie (ORCID: https://orcid.org/0000-0002-5032-1932)
- Sebastiaan J. van Hal (ORCID: https://orcid.org/0000-0001-5852-4155)
- Aimee Tan (ORCID: https://orcid.org/0000-0002-7257-1051)
- Christopher A. McDevitt (ORCID: https://orcid.org/0000-0003-1596-4841)
- Bart J. Currie (ORCID: https://orcid.org/0000-0002-8878-8837)
- Steven Y. C. Tong (ORCID: https://orcid.org/0000-0002-1368-8356)
- Mark R. Davies (ORCID: https://orcid.org/0000-0001-6141-5179)
- David B. Ascher (ORCID: https://orcid.org/0000-0003-2948-2413)
- Thanh Nguyen (ORCID: https://orcid.org/0000-0002-4150-5991)
- Glen Carter
- Matthew V. N. O'Sullivan
- Andrew J. Hayes
- Ravindra Dotel
Institutions
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- The University of Queensland (AU)
- The University of Melbourne (AU)
- Royal Prince Alfred Hospital (AU)
- Royal Ottawa Mental Health Centre (CA)
- Blacktown & Mount Druitt Hospital (AU)
- Westmead Hospital (AU)
- Charles Darwin University (AU)
- Menzies School of Health Research (AU)
- Peter Doherty Institute (AU)
- Monash Health (AU)
- Royal Darwin Hospital (AU)
- Monash University (AU)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-08-03
- DOI
- https://doi.org/10.1128/aac.00137-26
- Primary Topic
- Streptococcal Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00